McCachren S S, Greer P K, Niedel J E
Department of Medicine, Durham Veterans Administration Medical Center, NC 27705.
Arthritis Rheum. 1989 Dec;32(12):1539-45. doi: 10.1002/anr.1780321207.
Interleukin-1 (IL-1) may contribute to tissue destruction in rheumatoid arthritis, in part, by inducing messenger RNA (mRNA) that encodes interstitial collagenase. In human synovial fibroblasts in vitro, IL-1 induced collagenase mRNA accumulation 6 hours after being added to the cells. High levels of mRNA remained present for at least 48 hours after treatment. The rate of transcription of collagenase in isolated nuclei peaked after approximately 6 hours of treatment with IL-1 and declined thereafter, becoming nearly undetectable by 24 hours. The persistence of mRNA, in view of the transient peak of transcription, suggested that collagenase mRNA was stable in synovial fibroblasts. The half-life of collagenase mRNA after the synoviocytes were treated with actinomycin D was approximately 27 hours, both in the presence and in the absence of IL-1. It has been noted that induction of the expression of collagenase by phorbol esters requires fos protein synthesis and is mediated through a tetradecanoyl phorbol acetate response element in the 5'-flanking region of the gene. However, we found that cycloheximide, when added to synovial fibroblast cultures up to 6 hours after treatment with IL-1, inhibited the expression of collagenase mRNA. These results suggest that fos alone is unlikely to be sufficient for collagenase expression, and that additional factors, or alternative pathways, are involved in the induction of collagenase by IL-1.
白细胞介素-1(IL-1)可能在类风湿性关节炎中导致组织破坏,部分原因是通过诱导编码间质胶原酶的信使核糖核酸(mRNA)。在体外培养的人滑膜成纤维细胞中,IL-1加入细胞6小时后诱导胶原酶mRNA积累。处理后高水平的mRNA至少持续存在48小时。用IL-1处理分离细胞核中胶原酶的转录速率在大约6小时达到峰值,此后下降,到24小时几乎检测不到。鉴于转录的短暂峰值,mRNA的持续存在表明胶原酶mRNA在滑膜成纤维细胞中是稳定的。在用放线菌素D处理滑膜细胞后,无论有无IL-1,胶原酶mRNA的半衰期约为27小时。有人指出,佛波酯诱导胶原酶表达需要fos蛋白合成,并通过基因5'侧翼区域的十四酰佛波醇乙酸酯反应元件介导。然而,我们发现,在IL-1处理后长达6小时加入滑膜成纤维细胞培养物中的环己酰亚胺,抑制了胶原酶mRNA的表达。这些结果表明,单独的fos不太可能足以诱导胶原酶表达,并且在IL-1诱导胶原酶过程中涉及其他因子或替代途径。